-
Ferring announces new million euro educational initiative with International Federation of Fertility Societies (IFFS) and Elsevier
in Uncategorized onWorld leader in fertility treatments, Ferring Pharmaceuticals, announced today at the 2012 Updates in Infertility Treatment (UIT) meeting that…
0 -
Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (PENTASA®) in active ulcerative colitis
in Uncategorized onResults of a new study 1 presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate…
-
Ferring Pharmaceuticals acquires Cytokine PharmaSciences Inc.
in Uncategorized onFerring Pharmaceuticals (Ferring) announced today that it has completed the purchase of Cytokine PharmaSciences Inc. (CPSI) and its…
-
The untold impact of childhood bedwetting in later life
in Uncategorized onNew data, presented today at the International Continence Society (ICS) congress in Glasgow1, suggest that bedwetting…
-
New research reveals night-time toilet trips are not a trivial problem
in Uncategorized onNew data, presented at the International Continence Society (ICS) Congress, highlight the significant detrimental impact of nocturia…
-
New data demonstrating long-term benefits of FIRMAGON® (degarelix) for advanced hormone-dependant prostate cancer published in The Journal of Urology
in Uncategorized onNew data, published in the September issue of The Journal of Urology, showed that long-term use of FIRMAGON®…
-
MEGASET Study demonstrated effectiveness and tolerability of MENOPUR® after ICSI in GnRH antagonist cycles
in Uncategorized onNew data1, presented today at the European Society of Human Reproduction and Embryology (ESHRE) meeting, demonstrated the efficacy…
-
Ongoing extension study results provide further evidence for first-line use of FIRMAGON® (degarelix) in advanced prostate cancer
in Uncategorized onRecent data from the ongoing five-year FIRMAGON® (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of…
-
SMC Announces Acceptance of Degarelix (FIRMAGON®▼) for use within NHS Scotland
in Uncategorized onToday’s decision by the Scottish Medicines Consortium (SMC) (www.scottishmedicines.org.uk) to accept the use of FIRMAGON…
-
Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year
in Uncategorized onData recently presented on FIRMAGON® (degarelix) hormonal therapy for prostate cancer showed that long-term use beyond one year…
Uncategorized
Uncategorized